Slide 1: Business Update with Certain Financials for the Year Ending 2023
Business Update with Certain Financials for the Year Ending 2023 April 2, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” plans,” “intends,”
Slide 3: The Journey of Hope: Battling Retinitis Pigmentosa
The Journey of Hope: Battling Retinitis Pigmentosa They told me about Ocugen, and! started the study. They did the surgery. | can see alittle bit more in some areas that | didn't used to. You know, it was kind of dark, totally dark. For alot of people, it's not much. But for me, you know, it's a big
Slide 4: 2023 & YTD Accomplishments — Continued Clinical Momentum
2023 & YTD Accomplishments — Continued Clinical Momentum Cell Therapy NeoCart® ¥ Completed renovations on cGMP facility Y Received final clearance and occupancy certificate v Evaluating strategic value- building opportunities to further develop Phase 3 asset through commercialization — ocugen. 4 —
Slide 5: Modifier Gene Therapy: OCU400 for RP & LCA
Modifier Gene Therapy: OCU400 for RP & LCA Potential to address multiple genetic defects with a single product utilizing a gene-agnostic approach Ocugen is gradually growing its position within the gene therapy market as it progresses its programs Y Received concurrence from FDA on Phase 3 clinical
Slide 6: OCU410 & OCU410ST: Tackling Geographic Atrophy Secondary to Dry AMD & Stargardt Disease
OCU410 & OCU4I10OST : Tackling Geographic Atrophy Secondary to Dry AMD & Stargardt Disease OCU4I0 (ArMaDA Trial) Age related ¥ Announced Cohort! dosingcompletionin Phase /2 trialin March 2024 v_ Highaddressablemarket for GA/DAMD with limited therapeuticoptions— affects ~1OM peoplein the U.S.aloneand
Slide 7: Financial Update
—— Financial Update
Slide 8: Financial Update
Financial Update + TheCompany intends to restate its consolidated financial statements as of and for the year ended December 31, 2022, in connection with the filing of its 2023 Form 10-K. Similarly, the Company will include restated unaudited financial information for each of the first three quarter
Slide 9: Questions & Answers
Questions & Answers ocugen.
Slide 10: Execution of High Value Gene Therapies—Increase Value for Patients & Shareholders
Execution of High Value Gene Therapies— Increase Value for Patients & Shareholders Key Gene Therapy Milestones Achieved in 2023 ¢ First gene therapy program to get alignment with FDA for broad RP indication in Ph3 * Initiated dosing in OCU410 Ph1/2 clinical trial (dry AMD/GA) * Initiated dosing in O
Slide 11: Thank You
————— Thank You